Business Wire

Celltrion USA announces submission of the Biologics License Application (BLA) of novel subcutaneous formulation of CT-P13 to U.S. Food and Drug Administration

CHICAGO--(BUSINESS WIRE)--Celltrion USA today announced the submission of a Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act (a “stand-alone” BLA) for ...
TechHive

Proscenic P13 review: Effortless cordless cleaning

The Proscenic P13 makes a great supplementary vacuum for daily cleaning and quickly tackling small messes. The Proscenic P13 is the latest model in the brand’s line of cordless vacuums. It builds on ...
Business Wire

Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab (CT-P13 SC), highlighting dose escalation as an option for managing loss of response in ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced two-year results of subcutaneous infliximab (CT-P13 SC) dose escalation therapy at United European Gastroenterology (UEG) Week 2024 in ...
Yahoo

PINGU the Penguin Is Back in a New Animated Series

Famous claymation studio Aardman Animations is helping make the project, which is amazing considering how big of a Shaun the Sheep fan I am. Seriously, he is my profile picture on everything. Other ...
PharmiWeb

Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC) in inflammatory bowel disease (IBD) at the 19th ECCO Congress

Results of the two-year LIBERTY studies demonstrate that CT-P13 SC provides long-term clinical benefits and safety, with the convenience of subcutaneous (SC) administration, in the treatment of ...